Skip to main content
Japanese Journal of Cancer Research : Gann logoLink to Japanese Journal of Cancer Research : Gann
. 1995 Feb;86(2):135–139. doi: 10.1111/j.1349-7006.1995.tb03030.x

Interleukin‐12 Augments the Generation of Autologous Tumor‐reactive CD8+ Cytotoxic T Lymphocytes from Tumor‐infiltrating Lymphocytes

Soichi Kuge 1,2, Kazuhito Watanabe 1, Koji Makino 3, Yutaka Tokuda 2, Toshio Mitomi 2, Nobuo Kawamura 4, Sonoko Habu 1, and Takashi Nishimura 1,
PMCID: PMC5920748  PMID: 7730135

Abstract

Human tumor‐infiltrating lymphocytes (TIL) were obtained from breast cancer, renal cancer or neuroblastoma to investigate the generation of autologous tumor‐reactive CD8+ cytotoxic T lymphocytes (CTL). When TIL were cultured with interleukin (IL)‐2 (100 U/ml), the growth of TIL peaked around 8–10 days after the initiation of culture. In contrast, the proliferation of TIL cultured with IL‐2 plus IL‐12 peaked around 4–5 days after culture and tumor cells rapidly disappeared from the culture. To determine the generation of autologous tumor‐reactive CD8+ CTL, TIL‐derived CD8+ T cells were separated by FACStar. Both IL‐2‐activated and IL‐2 plus IL‐12‐activated TIL‐CD8+ T cells showed the same level of lymphokine‐activated killer activity against a variety of tumor cells. However, TIL‐CD8+ T cells activated with IL‐2 plus IL‐12 revealed greatly augmented cytotoxicity against autologous tumor cells compared with that induced by IL‐2 alone. The autologous tumor cell‐killing activity of TIL‐CD8+ CTL was significantly inhibited by the addition of F(ab)2 anti‐CD3 monoclonal antibody, indicating that these CTL recognize autologous tumor antigen through T cell receptor. These results imply that IL‐12 is a novel cytokine which facilitates the generation of autologous tumor‐reactive CD8+ CTL from TIL.

Keywords: IL‐12, TIL, CTL, Autologous tumor, Human

Full Text

The Full Text of this article is available as a PDF (605.9 KB).

REFERENCES

  • 1).Van den Bruggen , P. , Traversari , C. , Chomez , P. , Lurquin , C. , De Plaen , E. , Van den Eynde , B. , Knuth , A. and Boon , T.A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma . Science , 13 , 1643 – 1647 ( 1991. ). [DOI] [PubMed] [Google Scholar]
  • 2).Boon , T.Toward a genetic analysis of tumor rejection antigens . Adv. Cancer , 58 , 177 – 211 ( 1992. ). [DOI] [PubMed] [Google Scholar]
  • 3).Kawakami , Y. , Eliyahu , S. , Delgado , C. H. , Robbins , P. , Sakaguchi , K. , Appella , E. , Yannelli , J. R. , Adema , G. J. , Miki , T. and Rosenberg , S. A.Identification of human melanoma antigen recognized by tumor‐infiltrating lymphocytes associated with in vivo tumor rejection . Proc. Natl. Acad. Sci. USA , 91 , 6458 – 6462 ( 1994. ). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 4).Kobayashi , M. , Fitz , L. , Ryan , M. , Hewich , R. M. , Clark , S. C. , Loudon , S. , Sherman , F. , Perussia , B. and Trinchieri , G.Identification and characterization of natural killer cell stimulatory factor (NKSF), a cytokine with multiple biological effects on human lymphocytes . J. Exp. Med. , 170 , 827 – 845 ( 1989. ). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 5).Bloom , E. T. and Horvath , J. A.Cellular and molecular mechanism of the IL‐12‐induced increase in allospecific murine cytolytic T cell activity . J. Immunol. , 152 , 4242 – 4254 ( 1994. ). [PubMed] [Google Scholar]
  • 6).Cesano , A. , Visonneau , S. , Clark , S. C. and Santoli , D.Cellular and molecular mechanisms of activation of MHC nonrestricted cytotoxic cells by IL‐12 . J. Immunol. , 151 , 2943 – 2957 ( 1993. ). [PubMed] [Google Scholar]
  • 7).Hsieh , C.‐S. , Macatonia , S. E. , Tripp , C. S. , Wolf , S. F. , O'Garra , A. and Murphy , M.Development of TH1 CD4+ T cells through IL‐12 produced by Listeria ‐induced macrophages . Science , 260 , 547 – 549 ( 1993. ). [DOI] [PubMed] [Google Scholar]
  • 8).Brunda , M. J. , Luistro , L. , Warrier , R. R. , Wright , R. B. , Hubbard , B. R. , Murphy , M. , Wolf , S. F. and Gately , M. K.Antitumor and antimetastatic activity of interleukin 12 against murine tumors . J. Exp. Med. , 178 , 1223 – 1230 ( 1993. ). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 9).Bertagnolli , M. M. , Lin , B.‐Y. , Young , D. and Herrmann , S. H.IL‐12 augments antigen‐dependent proliferation of activated T lymphocytes . J. Immunol. , 149 , 3778 – 3783 ( 1993. ). [PubMed] [Google Scholar]
  • 10).Yanagida , T. , Kato , T. , Igarashi , O. , Inoue , T. and Nariuchi , H.Second signal activity of IL‐12 on the proliferation and IL‐2R expression of T helper cell‐1 clone . J. Immunol. , 152 , 4919 – 4928 ( 1994. ). [PubMed] [Google Scholar]
  • 11).Murphy , E. E. , Terres , G. , Macatonia , S. E. , Hsieh , C.‐S. , Mattson , J. , Lanier , L. , Wysocka , M. , Trinchieri , G. , Murphy , K. and O'Garra , A.B7 and interleukin 12 cooperate for proliferation and interferon γ production by mouse T helper clones that are unresponsive to B7 costimulation . J. Exp. Med. , 180 , 223 – 231 ( 1994. ). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 12).Andrews , J. V. R. , Schoof , D. D. , Bertagnolli , M. M. , Peoples , G. E. , Goedegebuure , P. S. and Eberlein , J.Immunomodulatory effects of interleukin‐12 on human tumor‐infiltrating lymphocytes . J. Immunother. , 14 , 1 – 14 ( 1993. ). [DOI] [PubMed] [Google Scholar]
  • 13).Zeh , H. J. , III , Hurd , S. , Storkus , W. J. and Lotze , M. T.Inter leukin‐12 promotes the proliferation and cytolytic maturation of immune effectors: implication for the immunotherapy of cancer . J. Immunother. , 14 , 155 – 161 ( 1993. ). [DOI] [PubMed] [Google Scholar]
  • 14).Rosenberg , S. A. , Packard , B. S. , Aebersold , P. M. , Solomon , D. , Topalian , S. L. , Toy , S. T. , Simon , P. , Lotze , M. T. , Yang , J. C. , Seipp , C. A. , Simpson , C. , Carter , C. , Bock , S. , Schwartzentruber , D. , Wei , J. P. and White , D. E.Use of tumor‐infiltrating lymphocytes and interleukin‐2 in the immunotherapy of patients with metastatic melanoma: a preliminary report . N. Engl. J. Med. , 319 , 1676 – 1680 ( 1988. ). [DOI] [PubMed] [Google Scholar]
  • 15).Nishimura , T. , Nakamura , Y. , Tsukamoto , H. , Takeuchi , Y. , Tokuda , Y. , Iwasawa , M. , Yamamoto , T. , Masuko , K. , Hashimoto , Y. and Habu , S.Human c‐erbB‐2 protooncogene product as a target for bispecific antibody‐directed adoptive tumor immunotherapy . Int. J. Cancer , 51 , 1 – 5 ( 1992. ). [DOI] [PubMed] [Google Scholar]
  • 16).Nishimura , T. , Yagi , H. , Ushiyama , Y. and Hashimoto , Y.Generation of lymphokine‐activated killer (LAK) cells from tumor‐infiltrating lymphocytes . Cell. Immunol. , 100 , 149 – 157 ( 1986. ). [DOI] [PubMed] [Google Scholar]

Articles from Japanese Journal of Cancer Research : Gann are provided here courtesy of Wiley

RESOURCES